Last reviewed · How we verify
NCT05244343
I VACCIN Hospitalization of COVID-19 Patients
trial in SARS CoV 2 Infection in 1,096 participants. Completed in 10 March 2022.
3 March 2022
Quick facts
| Lead sponsor | Eshmoun Clinical Research Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,096 |
| Start date | 25 January 2022 |
| Primary completion | 3 March 2022 |
| Estimated completion | 10 March 2022 |
| Sites | 1 location across Tunisia |
Conditions studied
- SARS CoV 2 Infection — all drugs for SARS CoV 2 Infection →
- COVID-19 — all drugs for COVID-19 →
Sponsor
Eshmoun Clinical Research Center
Who can join
18 and older, any sex, with SARS CoV 2 Infection or COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A REALLIFE evaluation of rate of hospitalized patients in Intensive Care Units and in medical Units of non -vaccinated patients vs vaccinated patients
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05244343
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS CoV 2 Infection
Currently open trials in the same condition.
- NCT07189936 — Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS · Phase 2 · recruiting
- NCT07197164 — Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients · Phase 2 · recruiting
- NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
- NCT06640387 — CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools · recruiting
- NCT06633835 — Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United St · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05244343 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eshmoun Clinical Research Center
- Last refreshed: 1 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05244343.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing